The Integrase Inhibitors Dolutegravir and Raltegravir Exert Proadipogenic and Profibrotic Effects and Induce Insulin Resistance in Human/Simian Adipose Tissue and Human Adipocytes

Impact of HIV/SIV infection and viral proteins on adipose tissue fibrosis and adipogenesis

(2019) Jennifer Gorwood et al.   AIDS

Lipid profile improvement in virologically suppressed HIV-1-infected patients switched to dolutegravir/abacavir/lamivudine: data from the SCOLTA project

(2019) Paola Bagella et al.   Infection and Drug Resistance

Metabolic complications affecting adipose tissue, lipid and glucose metabolism associated with HIV antiretroviral treatment

(2019) Claire Lagathu et al.   Expert Opinion On Drug Safety

Dual therapy combining raltegravir with etravirine maintains a high level of viral suppression over 96 weeks in long-term experienced HIV-infected individuals over 45 years on a PI-based regimen: results from the Phase II ANRS 163 ETRAL study

(2019) Christine Katlama et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV

(2019) Willem D.F. Venter et al.   NEW ENGLAND JOURNAL OF MEDICINE

Dolutegravir-Based or Low-Dose Efavirenz–Based Regimen for the Treatment of HIV-1

(2019)   NEW ENGLAND JOURNAL OF MEDICINE

Adipocytes impair efficacy of antiretroviral therapy

(2018) Jacob Couturier et al.   ANTIVIRAL RESEARCH

Oxidative Stress Inhibits Healthy Adipose Expansion Through Suppression of SREBF1-Mediated Lipogenic Pathway

(2018) Yosuke Okuno et al.   DIABETES

Adiponectin and the steatosis marker Chi3L1 decrease following switch to raltegravir compared to continued PI/NNRTI-based antiretroviral therapy

(2018) Obiageli Offor et al.   PLoS One

A retrospective analysis of weight changes in HIV-positive patients switching from a tenofovir disoproxil fumarate (TDF)- to a tenofovir alafenamide fumarate (TAF)-containing treatment regimen in one German university hospital in 2015–2017

(2018) Mario Gomez et al.   INFECTION

Relationships between Adipose Mitochondrial Function, Serum Adiponectin, and Insulin Resistance in Persons with HIV after 96 weeks of Antiretroviral Therapy

(2018) Todd Hulgan et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Progressive increases in fat mass occur in adults living with HIV on antiretroviral therapy, but patterns differ by sex and anatomic depot

(2018) Paula Debroy et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Brief Report

(2017) Jamison Norwood et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Dolutegravir-induced hyperglycaemia in a patient living with HIV

(2017) Milena McLaughlin et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

The FAT Score, a Fibrosis Score of Adipose Tissue: Predicting Weight-Loss Outcome After Gastric Bypass

(2017) Pierre Bel Lassen et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Short Communication: Comparative Evaluation of Coformulated Injectable Combination Antiretroviral Therapy Regimens in Simian Immunodeficiency Virus-Infected Rhesus Macaques

(2016) Gregory Q. Del Prete et al.   AIDS RESEARCH AND HUMAN RETROVIRUSES

Impact of elvitegravir on human adipocytes: Alterations in differentiation, gene expression and release of adipokines and cytokines

(2016) Ricardo Moure et al.   ANTIVIRAL RESEARCH

Body Composition Changes After Initiation of Raltegravir or Protease Inhibitors: ACTG A5260s

(2016) Grace A. McComsey et al.   CLINICAL INFECTIOUS DISEASES

Weight Gain and Incident Diabetes Among HIV-Infected Veterans Initiating Antiretroviral Therapy Compared With Uninfected Individuals

(2016) Melissa Herrin et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Higher Time-Updated Body Mass Index

(2016) John R. Koethe et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Changes in Insulin Resistance After Initiation of Raltegravir or Protease Inhibitors With Tenofovir-Emtricitabine: AIDS Clinical Trials Group A5260s

(2016) Sahera Dirajlal-Fargo et al.   Open Forum Infectious Diseases

Effects of raltegravir combined with tenofovir/emtricitabine on body shape, bone density, and lipids in African-Americans initiating HIV therapy

(2015) Laura Young et al.   HIV CLINICAL TRIALS

Short-term weight gain after antiretroviral therapy initiation and subsequent risk of cardiovascular disease and diabetes: the D:A:D study

(2015) AC Achhra et al.   HIV MEDICINE

Adipose Tissue Is a Neglected Viral Reservoir and an Inflammatory Site during Chronic HIV and SIV Infection

(2015) Abderaouf Damouche et al.   PLoS Pathogens

Differential penetration of raltegravir throughout gastrointestinal tissue

(2013) Kristine B. Patterson et al.   AIDS

Fibrosis and Adipose Tissue Dysfunction

(2013) Kai Sun et al.   Cell Metabolism

Increased oxidative stress in obesity: Implications for metabolic syndrome, diabetes, hypertension, dyslipidemia, atherosclerosis, and cancer

(2013) Morihiro Matsuda et al.   Obesity Research & Clinical Practice

LMNA Mutations Induce a Non-Inflammatory Fibrosis and a Brown Fat-Like Dystrophy of Enlarged Cervical Adipose Tissue

(2011) Véronique Béréziat et al.   AMERICAN JOURNAL OF PATHOLOGY

Effects of ritonavir-boosted darunavir, atazanavir and lopinavir on adipose functions and insulin sensitivity in murine and human adipocytes

(2011) Emilie Capel et al.   ANTIVIRAL THERAPY

Neutral Actions of Raltegravir on Adipogenesis, Glucose Metabolism and Lipolysis in 3T3-L1 Adipocytes

(2011) Patricia Perez-Matute et al.   CURRENT HIV RESEARCH

Comparison of the influence of four classes of HIV antiretrovirals on adipogenic differentiation: the minimal effect of raltegravir and atazanavir

(2010) Rumi Minami et al.   JOURNAL OF INFECTION AND CHEMOTHERAPY

HIV-associated lipodystrophy: from fat injury to premature aging

(2010) Martine Caron-Debarle et al.   TRENDS IN MOLECULAR MEDICINE